ESR1 and breast cancer: Additionally, Cook et al. utilized tamoxifen (TAM)-resistant MCF-7 cells and faslodex-resistant/tamoxifen cross-resistant LCC9 ER+ breast cancer cells to examine the effects of autophagy inhibition on anti-estrogen therapy [191].